[1]
E. L. M. ter Haar, J. M. P. A. van den Reek, K. Gaarn Du Jardin, A. Barbero-Castillo, E. M. G. J. . de Jong, and S. F. K. . Lubeek, “Efficacy and Safety of Tildrakizumab in Older Patients: Pooled Analyses of Two Randomized Phase III Clinical Trials (reSURFACE 1 and reSURFACE 2) Through 244 Weeks”, Acta Derm Venereol, vol. 103, p. adv17752, Oct. 2023.